Statin Treatment and the Occurrence of Hemorrhagic Stroke in Patients With a History of Cerebrovascular Disease
Stroke 39:497-502, Vergouwen,M.D.I.,et al, 2008
Hemorrhagic Stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Study
Neurol 70:2364-2370,2355, Goldstein,L.B.,et al, 2008
Toxic and Drug-Induced Myopathies
JNNP 80:832-838, Dalakas,M.C., 2009
Incidence of Hospitalized Rhabdomyloysis in Patients Treated With Lipid-Lowering Drugs
JAMA 292:2585-2590, Graham,D.J.,et al, 2004
Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin
Cardiovasc Drugs Ther 15:211-218, Bernini,F.,et al, 2001
Treating Nondementia Illnesses in Patients With Dementia
JAMA 283:3230-3235, Brauner,D.J. et al, 2000
Influence of Cholesterol on Survival After Stroke:Retrospective Study
BMJ 314:1584-1588, Dyker,A.G.,et al, 1997
Parkinsonism Unmasked by Lovastatin
Ann Neurol 37:685-686, Muller,T.,et al, 1995
Peripheral Neuropathy with Bezafibrate
BMJ 309:929, Ellis,C.J.,et al, 1994
HMG-CoA Reductase Inhibitor Therapy and Peripheral Neuropathy
Ann Int Med 120:970, Jacobs,M.B., 1994
Gemfibrozil-Induced Myopathy
Arch Int Med 151:1873-1874, Magarian,G.J.,et al, 1991
Cholesterol-Lowering Agent Myopathy (CLAM)
Neurol 41:1159-1160, London,S.F.,et al, 1991
Platelet-Inhibiting Drugs in the Prevention of Clinical Thrombotic Disease
NEJM 293:174, Genton,E.,et al, 1975
The Treatment of Cerebrovascular Disease with Clofibrate
VA Cooperative Study Group, Stroke 4:6841973., , 1973
Clofibrate for the Treatment of Occlusive CVD-Correspondence
NEJM 287:671, Hirsch,S.,et al, 1972